Robert's Feed
Jul 24, 2015
via Breakingviews

Breakdown: Watchdogs chew on health insurer deals

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Anthem and Cigna are the latest big U.S. health insurers to serve up a blockbuster merger. They and their peers need to satisfy a slew of regulators, though, before chowing down. Here’s a look at the agencies and the deals that officials may be asked to swallow in an already concentrated industry.

Jul 24, 2015

Breakingviews-Breakdown: Watchdogs chew on health insurer deals

By Robert Cyran

NEW YORK (Reuters Breakingviews) – Anthem and Cigna are the
latest big U.S. health insurers to serve up a blockbuster
merger. They and their peers need to satisfy a slew of
regulators, though, before chowing down. Here’s a look at the
agencies and the deals that officials may be asked to swallow in
an already concentrated industry.

WHAT TRANSACTIONS ARE IN THE WORKS?

Aetna has agreed to buy Humana for $37
billion, Anthem will pay $48 billion for Cigna,
and UnitedHealth Group might top either offer. The
companies seek the leverage that increased size would bring to
price negotiations with hospitals and drugmakers. Mergers could
also lead to cost savings and higher profit, a growing concern
for insurers since the Affordable Care Act, known as Obamacare,
required them to spend at least 80 percent of premiums on
medical care. And fewer rivals could mean more room to raise
premiums.

Jul 21, 2015
via Breakingviews

Apple has time on its side

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Apple has time on its side. The iPhone’s frenetic Chinese growth powered a 33 percent rise in revenue, to $50 billion in the three-month period ending June 27. Marginally softened forecasts for the next few months nevertheless knocked some $50 billion off Apple’s value. Limited information about Watch sales also disappointed. A little patience, however, will go a long way.

Jul 21, 2015
via Breakingviews

Apple has time on its side

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Apple has time on its side. The iPhone’s frenetic Chinese growth powered a 33 percent rise in revenue, to $50 billion in the three-month period ending June 27. Marginally softened forecasts for the next few months nevertheless knocked some $50 billion off Apple’s value. Limited information about Watch sales also disappointed. A little patience, however, will go a long way.

Jul 8, 2015
via Breakingviews

Microsoft gets $7.6 billion wakeup call from Nokia

Photo

[yospace_video ratio="16:9"]109453706[/yospace_video]

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Microsoft just got a $7.6 billion wakeup call from Nokia. The U.S. software goliath is writing off most of what it paid for a big piece of the Finnish mobile phone company in 2014. Microsoft’s M&A-related writedowns now tally about $14 billion over the past three years.

Jul 8, 2015
via Breakingviews

Microsoft gets $7.6 billion wakeup call from Nokia

Photo

[yospace_video ratio="16:9"]109453706[/yospace_video]

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Microsoft just got a $7.6 billion wakeup call from Nokia. The U.S. software goliath is writing off most of what it paid for a big piece of the Finnish mobile phone company in 2014. Microsoft’s M&A-related writedowns now tally about $14 billion over the past three years.

Jul 7, 2015
via Breakingviews

Latest pharma roll-up leaves lots of room to grow

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The latest pharmaceutical industry roll-up leaves lots of room to grow. Horizon Pharma’s $1.75 billion unsolicited offer for U.S. rival Depomed continues the sector’s M&A rave fueled by tax savings and cost cuts. The Irish bidder is a relatively recent arrival on the scene, though, and its low debt load and small size means it could easily expand.

Jul 7, 2015
via Breakingviews

Latest pharma roll-up leaves lots of room to grow

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The latest pharmaceutical industry roll-up leaves lots of room to grow. Horizon Pharma’s $1.75 billion unsolicited offer for U.S. rival Depomed continues the sector’s M&A rave fueled by tax savings and cost cuts. The Irish bidder is a relatively recent arrival on the scene, though, and its low debt load and small size means it could easily expand.

Jul 2, 2015
via Breakingviews

Healthcare M&A pumped after Obamacare booster shot

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Healthcare M&A is pumping up after an Obamacare booster shot. The U.S. Supreme Court decision last week to uphold President Barack Obama’s landmark reform signals the official start of a race to consolidate. Centene’s $6.3 billion purchase of Health Net gives the insurers an early lead, but bigger rivals like Cigna and Anthem may soon catch up.

Jul 2, 2015
via Breakingviews

Healthcare M&A pumped after Obamacare booster shot

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Healthcare M&A is pumping up after an Obamacare booster shot. The U.S. Supreme Court decision last week to uphold President Barack Obama’s landmark reform signals the official start of a race to consolidate. Centene’s $6.3 billion purchase of Health Net gives the insurers an early lead, but bigger rivals like Cigna and Anthem may soon catch up.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert